Ronnachai KongsakonSurasit Lochid-amnuayNattiya KapolOraluck PattanaprateepSilpakorn UniversityFaculty of Medicine, Ramathibodi Hospital, Mahidol University2020-01-272020-01-272019-05-01Value in Health Regional Issues. Vol.18, (2019), 47-5322121102221210992-s2.0-85056346201https://repository.li.mahidol.ac.th/handle/20.500.14594/50776© 2018 Objectives: To evaluate the adjuvant therapy of trastuzumab cost and quality-adjusted life-years (QALYs) in lifetime horizon and describe the use of an economic evaluation in supporting policy-making decisions in the treatment of early-stage breast cancer in Thailand. Methods: A Markov model was used to evaluate the cost effectiveness of 1-year adjuvant trastuzumab for patients with early-stage breast cancer who were considered human epidermal growth factor receptor 2/neu-positive with a societal perspective and lifetime horizon. The research variables were probability of health state change, health utility, and cost of treatment. A sensitivity analysis was conducted using probabilistic methods. A budget impact analysis was also performed. Results: The results revealed that the treatment cost and QALYs in the trastuzumab group yielded 4.59 QALYs. The incremental cost-effectiveness ratio was $3387 (THB 118 572; THB = Thai baht) per QALY. On the basis of the willingness-to-pay threshold in Thailand, a 1-year adjuvant trastuzumab treatment for breast cancer was a cost-effective therapy. Conclusions: A combination therapy that includes trastuzumab is a preferable choice and should be used in early-stage breast cancer treatment. The Thai government has listed trastuzumab on the National List of Essential Medicines to be used for the early stages of breast cancer since 2014.Mahidol UniversityEconomics, Econometrics and FinanceMedicineArticleSCOPUS10.1016/j.vhri.2018.08.004